Embecta faces securities fraud class action lawsuit, financial report crash caused stock price to plummet 57.8% in one day
Medical device company Embecta Corp. ( (symbol: EMBC) is facing a securities fraud class action lawsuit for allegedly misleading investors on its financial guidance. The deadline for investors to apply to serve as lead plaintiff is August 17, 2026. The lawsuit stems from the company's second-quarter financial report released on May 5, 2026. The financial report shows that Embecta not only failed to meet the previously given second quarter guidance, but also significantly reduced its full-year guidance for fiscal year 2026 by 46%, mainly due to weak sales of its pen needle business. The company also cut its dividend by 93%. On the day the news was announced (May 5), the stock price plummeted from the closing price of $9.25 on May 4 to $3.90, a single-day drop of as much as 57.8%, and the market value evaporated by hundreds of millions of dollars. The complaint alleges that during the class action period from November 25, 2025 to May 4, 2026, the defendant company and certain executives made materially false and misleading statements about the company’s business prospects. The company continued to reiterate its revenue guidance and the strong performance of its pen-needle business, even boasting that the business was "indestructible" weeks before the results hit. The plaintiff claimed that the company knew or ignored that its guidance was misleading and unachievable, but failed to disclose to investors major adverse facts such as competitive threats facing the U.S. pen needle market and the loss of customers. From a data comparison point of view, the company had previously promised that revenue for fiscal year 2026 would be US$1.071 billion to US$1.093 billion, and adjusted earnings per share would be US$2.80 to US$3.00. After the thunderstorm, it was revised to revenue of US$1.015 billion to US$1.035 billion, and adjusted earnings per share would be only US$1.55 to US$1.75. Revenue from pen needles alone was approximately US$53 million lower than previously expected, indicating significant customer concentration risks. Several shareholder rights law firms have launched class-action lawsuits. Investors who purchased or held company shares and suffered losses during the litigation can apply to the court to serve as lead plaintiff before August 17.